
MHRA recall M&A Pharmachem’s paracetamol due to fungal contamination
pharmafile | June 18, 2019 | News story | Manufacturing and Production | Contamination, MHRA, fungal, paracetamol, pharma
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall of M&A Pharmachem’s 500mg paracetamol tablets.
The tablets, which were produced in two separate batches of one thousand each, were found to be contaminated with the fungi Penicillium citrinium and Penicillium brevicompactum.
A number of tablets in each batch were found to be discoloured due to the fungal contamination.
However officials believe that patients have not taken the drugs as the discolouration is noticeable on opening the pack.
Wholesalers and healthcare professionals have been advised to stop supplying the affected batches as a quarantine has been put in place so that any remaining stock can be sent back to the supplier.
Louis Goss
Related Content

IMed Consultancy releases white paper on Digital Mental Health Technologies
IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …






